NSW Clinical Mass Spec Forum: Revolutionising Precision Oncology With Proteomics

ProCan® is an ambitious Australian-led initiative aiming to transform cancer diagnosis and treatment by integrating large-scale proteomics into clinical care. Established in 2016, ProCan has built the world’s largest pan-cancer proteome database, analysing over 32,000 tumour samples from more than 100 cancer types using advanced mass spectrometry.

This resource captures comprehensive protein profiles, enabling unprecedented insights into tumour biology and supporting the discovery of clinically relevant biomarkers. ProCan’s achievements include the development of robust, high-throughput workflows and the creation of a globally standardised platform for proteomic data generation. The ultimate goal is to translate these discoveries into the clinic.

This will be achieved through biomarker discovery and the development of targeted assays, such as the TargetQuant™ platform, initially for research and clinical trials, and ultimately for routine clinical use. These efforts are expected to accelerate precision oncology by enabling more accurate patient stratification and personalised therapy selection.

Register

Location

University of Technology Sydney, Building 4
Room CB04.05.430
Ultimo NSW
And online:  https://zoom.uts.edu.au/j/89363453890

The Royal Australasian College of Physicians publishes notices of events as a service to members. Such publication does not constitute endorsement or mandating of the event.